Metastatic Colorectal Cancer

The combination of panitumumab, ipilimumab and nivolumab induced responses among patients with metastatic colorectal cancer, according to phase 2 study results presented at Gastrointestinal Cancers Symposium.

Resection of colorectal liver metastases, often performed in conjunction with chemotherapy, can substantially extend survival — a fact that has been acknowledged for about 20 years.

Drinking coffee may reduce the risk for disease progression and death among patients with advanced or metastatic colorectal cancer, according to results of a prospective observational cohort study published in JAMA Oncology.

The FDA approved pembrolizumab for first-line treatment of patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient colorectal cancer.

The FDA granted fast track designation to fruquintinib for treatment of certain patients with metastatic colorectal cancer.

Trastuzumab deruxtecan demonstrated durable benefit among patients with HER2-expressing metastatic colorectal cancer, according to findings of the phase 2 DESTINY-CRC01 study presented during the ASCO20 Virtual Scientific Program.

First-line pembrolizumab extended PFS vs. chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to findings to be presented during the ASCO20 Virtual Scientific Program.

High consumption of fiber was linked to a reduced risk for break cancer, according to results of a meta-analysis published in Cancer. It was the top story in hematology/oncology last week.

Colorectal Cancer Awareness Month is observed in March.

Maintenance chemotherapy following initial treatment appeared to be more beneficial for patients with metastatic colorectal cancer than continuing a full induction regimen until disease progression, according to results of a meta-analysis of randomized clinical trials published in JAMA Oncology.